jueves, 22 de enero de 2026
Regular aerobic exercise slows a key marker of brain aging in midlife
https://www.news-medical.net/news/20260122/Regular-aerobic-exercise-slows-a-key-marker-of-brain-aging-in-midlife.aspx
A year of consistent aerobic activity didn’t just boost fitness; it shifted MRI-based brain age in early to midlife adults, suggesting exercise may help preserve brain health long before old age.
Editorial p71 Keeping children and young people safe in all their spaces The Lancet Child & Adolescent Health +++ +...
Muscle dysmorphia in adolescents and young adults
Jason M Nagata, MDa jason.nagata@ucsf.edu ∙ Jacqueline O Hur, BAa ∙ Ken Murakami, BAa ∙ Kyle T Ganson, PhDb ∙ Jinbo He, PhDc,d ∙ Stuart B Murray, PhDe ∙ et al.
https://www.thelancet.com/journals/lanchi/article/PIIS2352-4642(25)00283-4/abstract?utm_campaign=update-lanchi&utm_medium=email&dgcid=hubspot_update_feature_updatealerts_lanchi&_hsenc=p2ANqtz-9WEWWyoaB1O0diI0TTdvPq-VEx5HNCFjzsJQn0MMKp3ZLnZ9DAOcV60IUG50vwnJSXxiPTDotiB8fDYjR6WyuTx-QNvA&_hsmi=399686605&utm_content=399656663&utm_source=hs_email
Cybervictimisation and mental health conditions in young people: findings from a nationally representative longitudinal cohort
Frédéric Thériault-Couture, PhDa ∙ Flora Blangis, PhDa ∙ Niamh Dooley, PhDa,b ∙ Prof Helen L Fisher, PhDa,c ∙ Timothy Matthews, PhDd ∙ Prof Candice L Odgers, PhDe,f ∙ et al
https://www.thelancet.com/journals/lanchi/article/PIIS2352-4642(25)00311-6/fulltext?dgcid=hubspot_update_feature_updatealerts_lanchi&utm_campaign=update-lanchi&utm_medium=email&_hsenc=p2ANqtz-8TuULhQPw0zRRj5JwHQQLRCOr8pvV0SKygpKjHOo5mx_HPv0I-M7yOKcMDQOw2dSVI1s0wbLlMHjmYQl2IQQm1lj0Inw&_hsmi=399686605&utm_content=399656663&utm_source=hs_email
Diagnostic labels and clusters based on oxygen requirements in preterm infants with chronic lung disease: a data-driven exploratory cluster analysis in two independent cohorts
Damian Alvarez-Paggi, PhDa,b,c,d,* ∙ Anhar Ullah, PhDe,* ∙ Gaston Ofman, MDa ∙ Sadia Haider, PhDe ∙ Florencia Nowogrodzki, MDa ∙ Sara Fontanella, PhDe ∙ et al.
https://www.thelancet.com/journals/lanchi/article/PIIS2352-4642(25)00314-1/abstract?utm_campaign=update-lanchi&utm_medium=email&dgcid=hubspot_update_feature_updatealerts_lanchi&_hsenc=p2ANqtz-9E8QKlPQGy9KfH8Q0iqNzZduoemQn7Kmctvqf4fz8T3niGNdnz7tlvpYo65K7NL9YUDRUWiwjg9E3pj1JXBWL2JufHDg&_hsmi=399686605&utm_content=399656663&utm_source=hs_email
Editorial
p71
Keeping children and young people safe in all their spaces
The Lancet Child & Adolescent Health
https://www.thelancet.com/journals/lanchi/issue/vol10no2/PIIS2352-4642(25)X0014-6
Meet our 2026 Regional Representatives!
https://www.rarediseaseday.org/raising-youth-voices/
Raising Youth Voices is a new initiative designed to ensure that young people around the world are included in conversations that will define the next generation of policy, research, care, and community support for rare diseases. The event will bring together youth representatives from different regions to exchange experiences, build networks, and contribute to discussions on youth engagement, patient advocacy, and inclusive health policymaking.
8th TREAT-NMD® International Conference – Lisbon, 2026! 10 February @ 08:00 - 12 February @ 17:00 GMT
https://www.treat-nmd.org/event/8th-treat-nmd-international-conference-lisbon-2026/
TreatNMD® Conference
The 8th International TREAT-NMD® Conference will be taking place from 10-12 February at the Altis Grand Hotel in Lisbon, Portugal. This global event will bring together clinicians, researchers, patient advocates, and industry leaders under the theme "Addressing Challenges in a Changing World", where some of the most pressing issues in neuromuscular healthcare will be tackled. With keynote speakers, expert-led sessions, panel discussions, and networking opportunities, the conference promises to be a dynamic platform for collaboration and innovation. Tickets can be purchased via the official registration page. For corporate, group, or bulk registrations, please contact: education@treat-nmd.com.
TREAT-NMD 8th International Conference
Tue 10 Feb 2026 6:00 PM - Thu 12 Feb 2026 10:30 PM
https://www.tickettailor.com/events/treatnmd/1672102
A new global approach to childhood dementia
https://www.childhooddementia.org/globalagenda
Building global consensus: Why unified terminology matters for childhood dementia and all rare diseases
January 2026
The Member Comment article below was shared with EURORDIS-Rare Diseases Europe by Kris Kusidlo, Chairman of our member organisation Sanfilippo Initiative, and Community Representative of the Global Childhood Dementia Consensus Project Steering Committee.
https://www.eurordis.org/why-unified-terminology-matters-for-childhood-dementia/
Kris Kusidlo Joins Global Childhood Dementia Consensus Project Steering Committee
Kris Kusidlo, Chairman of the EURORDIS member organisation Sanfilippo Initiative, has been appointed as a Community Representative on the Global Childhood Dementia Consensus Project Steering Committee. In this role, Kris is helping to lead a pioneering international initiative bringing together over 150 experts from across the globe to establish unified terminology and definitions for childhood dementia conditions. The project addresses critical fragmentation affecting more than 145 rare genetic disorders that cause progressive cognitive decline and collectively affect approximately one in 2,900 births. Today, EURORDIS has published Kris' Member Comment article on the Project and the importance of unified terminology for rare diseases.
OUR GOAL IS TO FIND A CURE FOR DEVASTATING (SO FAR) FATAL INFANT DISEASE SANFILIPPO (MPSIII).
https://sanfilippoinitiative.org/en/home/
Increase your knowledge and skills in the rare disease space
https://openacademy.eurordis.org/
Fundamentals of Statistics in Clinical Trials
Eager to learn more about how the efficacy of treatments is measured? The EURORDIS Open Academy offers a course to understand the meaning of a "treatment effect" and different summary measures, as well as understanding the interpretation of confidence intervals and significance tests.
https://openacademy.eurordis.org/courses/statistics-clinical-trials/
Rita Francisco: More Clinical Trial Innovation Than You Can Imagine to be RealiseD January 2026
Rita Francisco: More Clinical Trial Innovation Than You Can Imagine to be RealiseD
January 2026
RealiseD is an Innovative Health Technology (IHI) project that aims to accelerate clinical trial innovation for rare and ultra-rare diseases. From participant recruitment to trial design, regulatory acceptance and clinical trial site standards, RealiseD is striving to make an impact on the clinical trial ecosystem. Will we succeed?
https://www.eurordis.org/rita-francisco-clinical-trial-innovation-realised/
EURORDIS Staff Blog
More Clinical Trial Innovation Than You Can Imagine to be RealiseD
In this article, our Patient Engagement Manager Rita Francisco introduces the RealiseD project that aims to accelerate clinical trial innovation for rare diseases. From participant recruitment to trial design, regulatory acceptance and clinical trial site standards, RealiseD is striving to make an impact on the clinical trial ecosystem. Rita shares what's coming up for the project, and the potential that it holds for the rare disease community.
How Patients Can Contribute to the Assessments of Health Technologies
https://www.mdpi.com/2001-6689/13/4/61
Journal of Market Access & Health Policy
How Patients Can Contribute to the Assessments of Health Technologies
In this article, our Information & Access to Therapies Director and Health Policy Advisor François Houÿez and our former Patient Engagement Manager and HTA/EUCAPA Project Coordinator Julien Delaye explain how patients and patient organisations can strengthen health technology assessment (HTA) at every stage. They also highlight why capacity building and training are essential - especially in light of the EU HTA Regulation - so patient experts can participate meaningfully in European-level processes.
The Journey of European Reference Networks
https://www.eurordis.org/rare-on-air/
Rare Disease Day bonus series
Get ready for Rare Disease Day by tuning into our Rare on Air Stories bonus series, where we highlight the lived experiences of people impacted by rare diseases across the globe. In the latest episode, Jessa shares how she has achieved remarkable milestones despite the challenges of chronic illness. You can also hear Ken's story, which offers a clear, grounded look at family, responsibility, and the resilience that grows quietly over years of caregiving. Christine also reflects on her perseverance following a life-threatening health crisis.
https://www.rarediseaseday.org/
Rare on Air: Małgorzata Kosla
Rare on Air: Małgorzata Kosla
https://www.eurordis.org/rare-on-air/
In this episode of Rare on Air, host Julien Poulain speaks with Małgorzata 'Gosia' Kosla, a rare disease advocate and mother of twins, Lena and Zuzia. Gosia’s journey into advocacy began in February 2022, when Lena was diagnosed with an ultra-rare neurodevelopmental condition caused by a mutation in the PACS2 gene. Over the past three years, Gosia and her family have helped build a global, patient-led research effort. Gosia also offers a candid perspective on patient-led research in Europe.
Raising Youth Voices
https://www.rarediseaseday.org/raising-youth-voices/
Raising Youth Voices
https://www.rarediseaseday.org/
The Raising Youth Voices event will take place this February in Barcelona! This initiative brings together the next generation of rare disease advocates from around the world, creating a space where young people can contribute their perspectives to Rare Disease Day 2026. If you won't be joining us in person, you can still follow the livestreamed event on the Rare Disease Day YouTube channel!
https://www.youtube.com/rarediseaseday
Open Academy x ERDERA Schools
https://openacademy.eurordis.org/data-ethics-ai-training/
Data, Ethics & AI training
Applications are now open for the second edition of the Data, Ethics and AI training, a hybrid programme designed for rare disease advocates ready to lead the conversation on data-driven research. This EURORDIS Open Academy programme includes monthly online sessions from March to July 2026, followed by in-person training in Barcelona on 14-15 September 2026. Participation is funded thanks to ERDERA, and places are limited to 20 patient advocates and early career researchers.
https://erdera.org/
RealiseD project
https://forms.office.com/pages/responsepage.aspx?id=p8acuKdXN0GCJGnn6gscVcF6gD6bPlVNiyuwfBlGt5ZUOU9TUUIyM1hKWjVQN042TkJNS1hYWDMzTi4u&route=shorturl
RealiseD is a project that brings together stakeholders to develop and validate new methods, standards and infrastructure to run better clinical trials for rare and ultra-rare diseases. EURORDIS is co-leading the project's Rare Disease Clinical Trial Enrolment Questionnaire to identify barriers to trial participation and how they can be addressed. The project will also host a four-part series
https://realised-ihi.eu/realised-webinars-driving-innovation-in-rare-disease-clinical-trials/
On 3–4 June 2026 in Prague and online, EURORDIS will host its 13th European Conference on Rare Diseases and Orphan Products (ECRD 2026) – Europe’s largest patient-led, policy-shaping event on rare diseases.
https://www.rare-diseases.eu/
Under the theme 'Rare Diseases in a Changing & Competitive Europe', ECRD 2026 will bring together people living with rare diseases, policymakers, researchers, clinicians, industry representatives and other stakeholders to advance concrete policy solutions that improve daily life for people living with a rare disease and their families.
The conference will also see the presentation of a European Blueprint for Rare Diseases, setting out policy priorities for an EU Action Plan and Europe’s contribution to the WHO Global Action Plan on Rare Diseases.
Read our latest article for an overview of the six thematic tracks and the key policy questions that will shape discussions at ECRD 2026.
ECRD 2026: Advancing rare disease policies in a changing and competitive Europe
January 2026
The 13th European Conference on Rare Diseases and Orphan Products (ECRD 2026) will take place in Prague and online on 3 and 4 June under the theme “Rare Diseases in a Changing & Competitive Europe: Shaping policies to address the unmet needs of people living with rare diseases”. The conference will bring together a broad range of stakeholders to advance concrete policy solutions that improve the lives of people living with a rare disease and their families.
https://www.eurordis.org/ecrd-2026-advancing-rare-disease-policies-in-a-changing-europe/
miércoles, 21 de enero de 2026
Results from the CARTITUDE-4 Clinical Trial in Multiple Myeloma ++++++ ++++++
CLINICAL PERSPECTIVES
Results from the CARTITUDE-4 Clinical Trial in Multiple Myeloma
https://checkrare.com/results-from-the-cartitude-4-clinical-trial-in-multiple-myeloma/
Binod Dhakal, MD, Associate Professor of Medicine at Medical College of Wisconsin, discusses results from the CARTITUDE-4 clinical trial in patients with multiple myeloma (MM).
Results of Part 1a of the OLYMPIA-3 Study of Odronextamab+Chemotherapy in Diffuse Large B-Cell Lymphoma
https://checkrare.com/results-of-part-1a-of-the-olympia-3-study-of-odronextamabchemotherapy-in-diffuse-large-b-cell-lymphoma/
Jean-Marie Michot, MD, Institut Gustave Roussy, France, discusses results from Part 1A (dose escalation) of the OLYMPIA-3 study of odronextamab plus chemotherapy in patients with diffuse large B-cell lymphoma (DLBCL).
Ibr+Ven Combination Therapy Versus Clb+Obi Combination Therapy in Chronic Lymphocytic Leukemia
https://checkrare.com/ibrven-combination-therapy-versus-clbobi-combination-therapy-in-chronic-lymphocytic-leukemia/
Paolo Ghia, MD, PhD, Professor of Medical Oncology at the Università Vita-Salute San Raffaele in Milan, Italy, discusses data comparing ibrutinib plus venetoclax combination therapy with chlorambucil + obinutuzumab combination therapy in patients with chronic lymphocytic leukemia (CLL).
Results from the LINKER-MM4 Clinical Trial in Multiple Myeloma
https://checkrare.com/results-from-the-linker-mm4-clinical-trial-in-multiple-myeloma/
Robert Orlowski, MD, PhD, Professor of Medicine at the University of Texas MD Anderson Cancer Center, discusses results from the LINKER-MM4 clinical trial testing Lynozyfic (linvoseltamab) to treat patients with newly diagnosed multiple myeloma (MM).
The cAMeLot-2 Trial Testing Bleximenib Combination Therapy for Acute Myeloid Leukemia
https://checkrare.com/the-camelot-2-trial-testing-bleximenib-combination-therapy-for-acute-myeloid-leukemia/
Elias Jabbour, MD, MD Anderson Cancer Center at the University of Texas, discusses the cAMeLot-2 study design of bleximenib combination therapy for patients with acute myeloid leukemia (AML).
Results of the BUTTERFLY Clinical Trial in Pediatric Patients With Dravet Syndrome
https://checkrare.com/results-of-the-butterfly-clinical-trial-in-pediatric-patients-with-dravet-syndrome/
Joseph Sullivan, MD, Professor of Neurology and Pediatrics at the University of California at San Francisco, discusses the results of the BUTTERFLY clinical trial in pediatric patients with Dravet syndrome.
Phase 3 Data of Vonvendi for the Treatment of Von Willebrand Disease
https://checkrare.com/phase-3-data-of-vonvendi-for-the-treatment-of-von-willebrand-disease/
Shayla Bergmann, MD, Pediatric Hematologist/Oncologist at the Medical University of South Carolina, discusses phase 3 data of Vonvendi for the treatment of Von Willebrand disease (VWD).
Broader Dosing Ranges of Skytrofa Now Available for Growth Hormone Deficiency
https://checkrare.com/broader-dosing-ranges-of-skytrofa-now-available-for-growth-hormone-deficiency/
Lisa Abbott, MD, endocrinologist with Northern Nevada Endocrinology, discusses the expansion of broader dosing ranges of Skytrofa (lonapegsomatropin) now available for the replacement of endogenous growth hormone in adults with growth hormone deficiency (GHD).
Sotatercept for Pulmonary Arterial Hypertension Within the First Year After Diagnosis
https://checkrare.com/sotatercept-for-pulmonary-arterial-hypertension-within-the-first-year-after-diagnosis/
A recent study, published in the New England Journal of Medicine, looked at the effects of sotatercept for pulmonary arterial hypertension (PAH) within the first year after diagnosis.
Long-Term Data With Dawnzera for the Treatment of Hereditary Angioedema
https://checkrare.com/long-term-data-with-dawnzera-for-the-treatment-of-hereditary-angioedema/
Michael Manning, MD, Allergist and Immunologist, discusses long-term data with Dawnzera (donidalorsen) for the treatment of patients with hereditary angioedema (HAE).
Effects of Vitusiran on Cardiac Structure and Function in Patients With Transthyretin Amyloidosis With Cardiomyopathy
https://checkrare.com/effects-of-vutrisiran-on-cardiac-structure-and-function-in-patients-with-transthyretin-amyloidosis-with-cardiomyopathy/
A recent study, published in Nature Medicine, looked at the effects of vutrisiran on cardiac structure and function in patients with transthyretin amyloidosis with cardiomyopathy (ATTR-CM) through a secondary analysis of the HELIOS-B clinical trial.
Advancing Thyroid Eye Disease Care: Integrating Tepezza, New Technology, and Optimizing Multidisciplinary Teams
https://checkrare.com/advancing-thyroid-eye-disease-care-integrating-tepezza-new-technology-and-optimizing-multidisciplinary-teams/
Maja Kostic, MD, PhD, neuro-ophthalmologist at Bascom Palmer Eye Institute and Assistant Professor of Ophthalmology at the University of North Carolina at Chapel Hill, discusses advancing thyroid eye disease (TED) care.
RARE DISEASE LEARNING CENTERS +++ +++ +++ +++
RARE DISEASE LEARNING CENTERS
Rett Syndrome
https://checkrare.com/rett-syndrome/
Rett syndrome is a multisystem disorder that primarily affects girls. Only in rare cases are boys affected (who may experience more severe symptoms). Multiple loss-of-function mutations to the MECP2 gene are the cause of Rett syndrome.
Aromatic L-Amino Acid Decarboxylase (AADC) Deficiency
https://checkrare.com/aromatic-l-amino-acid-decarboxylase-aadc-deficiency/
Aromatic L-amino acid decarboxylase (AADC) deficiency is a rare, genetic disorder that affects the central nervous systems of young patients. AADC deficiency is caused by defect in the dopa decarboxylase (DDC) gene, which leads to a reduction in the critical neurotransmitters dopamine, norepinephrine, epinephrine, and melatonin in the brain.
WHIM Syndrome
https://checkrare.com/whim-syndrome/
WHIM syndrome is a rare, congenital primary immunodeficiency disorder associated with severe neutropenia that affects all ages. The acronym “WHIM” stands for (W)arts, (H)ypogammaglobulinemia, (I)nfections, and (M)yelokathexis. Myelokathexis refers to an abnormal retention of white blood cells, in the bone marrow, that causes a reduction of immune fighting white blood cells, and most notably the reduction of neutrophils and lymphocytes.
CME PROGRAMS
Transforming Clinical Outcomes with Early Treatment of Lysosomal Disorders
https://checkrare.com/learning/p-transforming-clinical-outcomes-with-early-treatment-of-lysosomal-disorders/
Ozlem Goker-Alpan MD, David F. Kronn, MD, Uma Ramaswami FRCPCH, MD, Liz Jalazo, MD, and Lindsay Torrice MSN, CPNP-PC, examine the evidence available to address how to monitor, and possibly treat, children with lysosomal diseases that were diagnosed by newborn screening or soon after birth.
CREDITS: 1.00 CME | DURATION: 1 hour
EXPIRES: 4/3/2026 | FEE: $0
Consider Rare: Suspecting and Diagnosing Hereditary Angioedema
https://checkrare.com/learning/p-consider-rare-suspecting-and-diagnosing-hereditary-angioedema/
Jonathan A Bernstein, MD, Professor of Medicine at the University of Cincinnati describes the early symptoms of HAE and its clinical relevance and best practices to diagnose HAE more efficiently to reduce diagnostic delays.
CREDITS: 0.5 CME | DURATION: 0.5 hours
EXPIRES: 5/15/2026 | FEE: $0
Fabry Disease Research Highlights
https://checkrare.com/learning/p-fabry-disease-research-highlights-2025/
Eric Wallace, MD, Professor of Medicine, Department of Nephrology at the University of Alabama Medical School, describes the latest research being presented to better manage individuals with Fabry disease and its clinical relevance.
CREDITS: 0.5 CME | DURATION: 0.5 hours
EXPIRES: 5/15/2026 | FEE: $0
GRIDS 2025:
Current Issues in Gene Therapies for Lysosomal Disorders
https://checkrare.com/learning/p-grids2025-session6-current-issues-in-gene-therapies-for-lysosomal-disorders/
Shunji Tomatsu, MD, PhD, Alessandra d’Azzo, PhD, Merve Emecen Sanli, MD, and Ryan Colburn, patient with Pompe disease and president of Odimm Inc, discuss new and emerging gene therapies for lysosomal disorders.
CREDITS: 1.75 CME | DURATION: 1.75 hours
EXPIRES: 12/31/2026 | FEE: $0
AI in Medicine: Transforming the Landscape of Tissue-Based Diagnostics
https://checkrare.com/learning/p-grids2025-session1-ai-in-medicine-transforming-the-landscape-of-tissue-based-diagnostics/
Behzad Najafian, MD, Professor, Department of Laboratory Medicine & Pathology, Department of Medicine at the University of Washington, Washington, USA discusses the use of artificial intelligence in identifying and managing lysosomal disorders.
CREDITS: 1.0 CME | DURATION: 1.0 hours
EXPIRES: 12/31/2026 | FEE: $0
Nanotechnology and Lysosomal Disorders
https://checkrare.com/learning/p-grids2025-session2-nanotechnology-and-lysosomal-disorders/
Stephan Stern, PhD, DABT, and Ruben Boado, PhD, Professor of Medicine, University of California at Los Angeles, California, discuss the use of nanotechnology in the treatment of lysosomal disorders.
CREDITS: 0.75 CME | DURATION: 0.75 hours
EXPIRES: 12/31/2026 | FEE: $0
Organoids and Lab-Grown Models in Lysosomal Disorders
https://checkrare.com/learning/p-grids2025-session3-organoids-and-lab-grown-models-in-lysosomal-disorders/
Mia Horowitz, PhD, Tel Aviv University, Aitor Aguirre, PhD, Michigan State University, and Ying Sun, PhD, University of Cincinnati, discuss the use of organoid models in lysosomal disorder research and drug development.
CREDITS: 1.5 CME | DURATION: 1.5 hours
EXPIRES: 12/31/2026 | FEE: $0
Expanded Applications of AI in Lysosomal Disorders
https://checkrare.com/learning/p-grids2025-session4-expanded-applications-of-ai-in-lysosomal-disorders/
Oral Alpan, MD, Svenja Keller, PhD student, University of Zurich, Shoshana Revel-Vilk, MD, PhD, Director, Gaucher Unit & Pediatric Hematology/Oncology Unit, Shaare Zedek Medical Center, Patrick Deegan, MD, University of Cambridge, and Ravi Kamath, MD, PhD, Head of Musculoskeletal Radiology, Inova Health System, discuss the applications of AI in the diagnosis and treatment of lysosomal disorders.
CREDITS: 2.0 CME | DURATION: 2.0 hours
EXPIRES: 12/31/2026 | FEE: $0
Theranostics and Lysosomal Disorders
https://checkrare.com/learning/p-grids2025-session5-theranostics-and-lysosomal-disorders/
Duarte C. Barral, PhD, NOVA University of Lisbon, Nuno Raimundo, PhD, Penn State College of Medicine, Betul Celik, PhD, Postdoctoral Fellow, Nemours Children’s Health, and Gregory Newby, PhD, Assistant Professor, Johns Hopkins School of Medicine, discuss the principles of theranostics and its application in lysosomal disorders.
Week 52 Results of TransCon CNP (Navepegritide) in Children With Achondroplasia +... +++++ +++++
CLINICAL PERSPECTIVE
https://checkrare.com/
Efficacy of Pozelimab + Cemdisiran To Treat Paroxysmal Nocturnal Hemoglobinuria
https://checkrare.com/efficacy-of-pozelimab-cemdisiran-to-treat-paroxysmal-nocturnal-hemoglobinuria/
Jun Ho Jang, MD, PhD, Professor, Division of Hematology-Oncology at Samsung Medical Center, discusses results from an open-label extension study testing pozelimab plus cemdisiran combination therapy in patients with paroxysmal nocturnal hemoglobinuria (PNH), who previously received the combination therapy or received ravulizumab.
Duchenne Muscular Dystrophy (DMD) and Metachromatic Leukodystrophy (MLD) Recommended Uniform Screening Panel
https://checkrare.com/duchenne-muscular-dystrophy-dmd-and-metachromatic-leukodystrophy-mld-recommended-uniform-screening-panel/
The U.S. Department of Health and Human Services (HHS) has approved the addition of Duchenne muscular dystrophy (DMD) and metachromatic leukodystrophy (MLD) to the Recommended Uniform Screening Panel (RUSP).
Results of the BUTTERFLY Clinical Trial in Pediatric Patients With Dravet Syndrome
https://checkrare.com/results-of-the-butterfly-clinical-trial-in-pediatric-patients-with-dravet-syndrome/
Joseph Sullivan, MD, Professor of Neurology and Pediatrics at the University of California at San Francisco, discusses the results of the BUTTERFLY clinical trial in pediatric patients with Dravet syndrome.
Phase 3 Data of Vonvendi for the Treatment of Von Willebrand Disease
https://checkrare.com/phase-3-data-of-vonvendi-for-the-treatment-of-von-willebrand-disease/
Shayla Bergmann, MD, Pediatric Hematologist/Oncologist at the Medical University of South Carolina, discusses phase 3 data of Vonvendi for the treatment of Von Willebrand disease (VWD).
Broader Dosing Ranges of Skytrofa Now Available for Growth Hormone Deficiency
https://checkrare.com/broader-dosing-ranges-of-skytrofa-now-available-for-growth-hormone-deficiency/
Lisa Abbott, MD, endocrinologist with Northern Nevada Endocrinology, discusses the expansion of broader dosing ranges of Skytrofa (lonapegsomatropin) now available for the replacement of endogenous growth hormone in adults with growth hormone deficiency (GHD).
Sotatercept for Pulmonary Arterial Hypertension Within the First Year After Diagnosis
https://checkrare.com/sotatercept-for-pulmonary-arterial-hypertension-within-the-first-year-after-diagnosis/
A recent study, published in the New England Journal of Medicine, looked at the effects of sotatercept for pulmonary arterial hypertension (PAH) within the first year after diagnosis.
Long-Term Data With Dawnzera for the Treatment of Hereditary Angioedema
https://checkrare.com/long-term-data-with-dawnzera-for-the-treatment-of-hereditary-angioedema/
Michael Manning, MD, Allergist and Immunologist, discusses long-term data with Dawnzera (donidalorsen) for the treatment of patients with hereditary angioedema (HAE).
Effects of Vutrisiran on Cardiac Structure and Function in Patients With Transthyretin Amyloisdosis With Cardiomyopathy
https://checkrare.com/effects-of-vutrisiran-on-cardiac-structure-and-function-in-patients-with-transthyretin-amyloidosis-with-cardiomyopathy/
A recent study, published in Nature Medicine, looked at the effects of vutrisiran on cardiac structure and function in patients with transthyretin amyloidosis with cardiomyopathy (ATTR-CM) through a secondary analysis of the HELIOS-B clinical trial.
Kygevvi for Patients With Thymidine Kinase 2 Deficiency
https://checkrare.com/kygevvi-for-patients-with-thymidine-kinase-2-deficiency/
Kim Moran, Head of U.S. Rare Diseases at UCB, discusses the approval of Kygevvi (doxecitine and doxribtimine) for patients with thymidine kinase 2 deficiency (TK2d).
Positive Topline Results from the CALIBRATE Trial of Encaleret in Patients With Autosomal Dominant Hypocalcemia Type 1
https://checkrare.com/positive-topline-results-from-the-calibrate-trial-of-encaleret-in-patients-with-autosomal-dominant-hypocalcemia-type-1/
Michael A. Levine, MD, ML, Children’s Hospital of Philadelphia, discusses positive topline results from the CALIBRATE trial of encaleret in patients with autosomal dominant hypocalcemia type 1 (ADH1).
A Patient’s Diagnostic Journey With Systemic Mastocytosis
https://checkrare.com/a-patients-diagnostic-journey-with-systemic-mastocytosis/
Joan Smith, patient with systemic mastocytosis, discusses her diagnostic journey with systemic mastocytosis (SM).
Results from the ElevAATe Clinical Trial of Efdoralprin Alfa for Patients With AAT Deficiency
https://checkrare.com/results-from-the-elevaate-clinical-trial-of-efdoralprin-alfa-for-patients-with-aat-deficiency/
Alaa Hamed, MD, Global Head of Medical Affairs Rare Diseases at Sanofi, discusses results from the ElevAATe clinical trial of efdoralprin alfa for the treatment of patients with alpha-1 antitrypsin deficiency (AATD).
2026 Orphan Drugs: PDUFA Dates and FDA Approvals +++++
FDA NEWS
2026 Orphan Drugs: PDUFA Dates and FDA Approvals
https://checkrare.com/2026-orphan-drugs-pdufa-dates-and-fda-approvals/
Rare diseases and orphan drugs are at the forefront of novel development and groundbreaking research. Almost half of all novel medications approved by the U.S. Food and Drug Administration (FDA) are orphan drugs.
Aqvesme (Mitapivat) Approved for Treatment of Anemia in Alpha- and Beta-Thalassemia
https://checkrare.com/fda-approves-aqvesme-mitapivat-for-treating-anemia-in-alpha-and-beta-thalassemia/
The U.S. FDA has approved Aqvesme (mitapivat) for the treatment of anemia in adults with alpha- or beta-thalassemia.
FDA Approves Obstructive Hypertrophic Cardiomyopathy Treatment
https://checkrare.com/fda-approves-obstructive-hypertrophic-cardiomyopathy-treatment/
The U.S. FDA has approved Myqorzo (aficamten) for the treatment of adults with symptomatic obstructive hypertrophic cardiomyopathy (oHCM).
Gene Therapy (Waskyra) Approved for Patients with Wiskott-Aldrich Syndrome
https://checkrare.com/fda-approves-gene-therapy-waskyra-for-patients-with-wiskott-aldrich-syndrome/
The U.S. FDA has approved Waskyra (etuvetidigene autotemcel) for the treatment of patients ages 6 months and older with Wiskott-Aldrich syndrome (WAS).
FDA Approves Oral Prophylactic Therapy (berotralstat) for Pediatric Patients With Hereditary Angioedema
https://checkrare.com/fda-approves-oral-prophylactic-therapy-berotralstat-for-pediatric-patients-with-hereditary-angioedema/
The U.S. FDA has approved Orladeyo (berotralstat) for prophylactic therapy in pediatric patients with hereditary angioedema (HAE) ages 2 to 12 years of age.
Current Status of Gene Therapies in Rare Neuromuscular Disorders +++++
FEATURED ARTICLES
Current Status of Gene Therapies in Rare Neuromuscular Disorders
https://checkrare.com/current-status-of-gene-therapy-in-rare-neuromuscular-disorders/
Alan Beggs, PhD and Julie A Parsons, MD, discuss the current status of gene therapies in rare neuromuscular disorders.
Current Status of Gene Therapy in Lysosomal Storage Disorders
https://checkrare.com/current-status-of-gene-therapy-in-lysosomal-storage-disorders/
Nicola Longo MD, PhD and Mark Roberts, MD, discuss the current status of gene therapies in lysosomal storage disorders.
Catching the Clues, Changing the Course of Lysosomal Storage Disorders
https://checkrare.com/catching-the-clues-changing-the-course-of-lysosomal-storage-disorders/
Yoshikatsu Eto, MD, PhD, Nicole Muschol, MD, Patrício Aguiar, MD, and Robert Hopkin, MD, explore the patient journey across the lysosomal storage disorder (LSD) continuum, focusing on persistent gaps in recognition, diagnosis, timely treatment initiation, and long-term care.
The Genetics of Epilepsy: The Importance of Identifying Underlying Causes
https://checkrare.com/the-genetics-of-epilepsy-the-importance-of-identifying-underlying-causes/
Isabella Herman, MD, PhD, and Tara Adams, mother of two daughters with epilepsy discuss the challenges of accurate diagnosis and treatment of epilepsy.
Survey Finds Wide-Ranging Impact of X-Linked Hypophosphatemia (XLH) on Patient Experiences
https://checkrare.com/survey-finds-wide-ranging-impact-of-x-linked-hypophosphatemia-on-patient-experiences/
Al Freedman, PhD, Rare Disease Psychologist and Rare Dad, and Jill H. Simmons, MD, Endocrinologist at Vanderbilt University Medical Center in Nashville, Tennessee highlight the burden of XLH on personal finances and out-of-pocket costs, overall health—physical, mental, and social—and access to expert care.
HAMRLNC: a comprehensive and scalable pipeline for integrated epitranscriptomic analysis Chosen E. Obih [1,†] , Jiatong Li [2,3,†] , Giovanni Melandri [1,4] , Duke Pauli [1,4] , Eric Lyons [1] , Andrew D. L. Nelson [5] , Brian D. Gregory* [2]
https://www.academia.edu/3064-9765/2/4/10.20935/AcadMolBioGen8059
As sequencing technologies advance and costs decline, there has been a surge in the application of RNA sequencing (RNA-seq) to understand the effects of gene expression regulation on specific biological processes. In addition to the typical uses of RNA-seq for transcriptomics, gene annotation, novel gene discovery, and network analysis, these data can enable a deeper understanding of cellular processes through the identification of RNA modifications (epitranscriptome) and long non-coding RNAs (lncRNAs). To expedite discovery, we developed a portable, centralized computational pipeline for the high-throughput annotation of modified ribonucleotides and long non-coding ribonucleic acids (HAMRLNC). HAMRLNC differs from existing methods by integrating three workflows for transcript abundance quantification, RNA modification inference, and lncRNA annotation using the same RNA-seq pre-processing and mapping steps. This facilitates reproducibility across multiple analyses and allows researchers to perform post hoc analyses of archived sequencing data. In addition, we include novel analysis features to enable downstream visualization of annotated modified RNAs. HAMRLNC generates over a dozen well-defined and labeled figures as output, including gene ontology heatmaps, modification enrichment landscapes, and modification clustering statistics.
Advances in T-DNA integration analysis: from classical methods to next-generation sequencing
Naveen Kumar Singh, Pawan Shukla, Ranjana Gautam, Jinu Jacob, Pulugurtha Bharadwaja Kirti
Volume 2, Issue 4
https://www.academia.edu/journals/academia-molecular-biology-and-genomics/articles?source=journal-top-nav
When medicine lags: how US healthcare falls behind, what it costs us and how to fix it Written by Kaily Ball
https://rarerevolutionmagazine.com/when-medicine-lags-how-us-healthcare-falls-behind-what-it-costs-us-and-how-to-fix-it/
Kaily Ball is a writer, researcher and patient advocate. She gives her insights into the healthcare challenges people with rare conditions face in the US and outlines some of the global models she feels could be implemented to improve diagnosis and care
The United States is home to some of the world’s most brilliant researchers and some of the most advanced medical technologies ever created.1,2 Yet for patients navigating complex, rare or poorly understood conditions, the experience often feels primitive.3,4 Diagnoses come late or not at all, and treatments are delayed.5,6,7 All the while, families drain their savings and watch their health deteriorate.8,9
Here’s the paradox: Americans spend more on healthcare than anyone else in the world—an average of $13,432 per person in 2023, nearly double the $7,393 per person that other wealthy countries spend.10 Healthcare eats up 17.6% of US GDP, compared to about 11% elsewhere.11,12 Yet despite the highest price tag, we consistently rank near the bottom for access, equity and outcomes.13
It’s not that better care isn’t possible. Other nations have shown what happens when systems modernise: patients are diagnosed earlier, treated faster and supported more fully, often at a fraction of what we pay.14,15,16,17,18
Thoracic outlet syndrome: a tale of two standards
When I was working through my own thoracic outlet syndrome diagnosis, I stumbled across something that perfectly illustrates the problem. The US and Europe don’t even define the condition the same way.
Here in the US, to be diagnosed with arterial thoracic outlet syndrome (aTOS), you need proof of damage—a clot, an intimal injury or an aneurysm that shows up on imaging. Without that, even if your arteries are clearly being compressed, your condition is classified as neurogenic TOS (nTOS) instead. That label limits treatment options and delays the interventions that could prevent lasting damage.19,20
In Europe, compression plus symptoms is enough to call it what it is: aTOS. Their clinicians treat based on what’s actually happening physiologically, not just what’s visible on an image. That difference means earlier recognition, earlier intervention and fewer patients forced to deteriorate before they’re “sick enough” to qualify for help.21
That delay isn’t just cruel. It’s expensive. Delayed diagnoses lead to longer clinical journeys, redundant testing and more severe complications. All of which drive up costs that, in the US, are already the highest in the world.6
Sexual Orientation–Related Differences in Alcohol Use and Suicide Death
https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2844078?utm_campaign=morning_rounds&utm_medium=email&_hsenc=p2ANqtz-8BxwHg3ZKbUXCSFXt-nTzwUD4OBtv8qI-A0np3L5Cxaf6_sKku7NpOAKLT21pMLojGiwOQu63Cna1eKyNR58bYt1r_NQ&_hsmi=399577210&utm_content=399577210&utm_source=hs_email
Queer women have heightened risk of alcohol-related suicide
Alcohol-related health problems have been increasing for decades in the U.S. But often overlooked is that LGBTQ+ people, particularly queer women, consume more alcohol than their straight peers. These populations also have higher rates of suicide. A study published Friday in JAMA Network Open used data from the National Violent Death Reporting System to analyze the intersection of these two health issues.
Data on suicides from 2013 to 2021 showed that when lesbian, gay, and bisexual women died by suicide, their deaths were 38% more likely to involve alcohol use than straight women. There was not an increased risk for gay men compared to their straight counterparts.
The study authors note that they weren’t able to analyze data on the deaths of transgender people, despite the population’s increased risk for both suicide and alcohol use. This isn’t because the Trump administration erased data on transgender identity from the database — which they did, study author Sarah McKetta confirmed to me over email. The researchers got access to the data before the Trump administration started. But even though there was a template for coroners or medical examiners to indicate if somebody was transgender, McKetta explained, there was no clear way to provide the person’s actual gender identity.
By the numbers: America’s alcohol-related health problems are rising fast
https://www.statnews.com/2024/06/27/alcohol-related-health-problems-rise/?utm_campaign=morning_rounds&utm_medium=email&_hsenc=p2ANqtz-8Wy_7GYrfFblQIZMLn8I0WNsUJOsGqNgpQbqyiIj-1YgIAd6jLbtHDZIdJ1sWiPRonM6Z9zY5rllHbyD2GQLqhZXf2Eg&_hsmi=399577210&utm_content=399577210&utm_source=hs_email
Senior CDC official: Loss of measles elimination status in U.S. would be ‘cost of doing business’ Agency’s principal deputy director suggests transmission inevitable due to international travel
https://www.statnews.com/2026/01/20/cdc-measles-briefing-lost-elimination-status-cost-of-doing-business/
By Helen BranswellJan. 20, 2026
Infectious Diseases Correspondent
Is ‘shared decision-making’ being hijacked by U.S. health officials to sow doubt about vaccines?
Researchers say the Trump administration’s vaccine guidance is distorting the term’s meaning
https://www.statnews.com/2026/01/20/shared-decision-making-vaccine-guidance-twists-meaning-of-term/
By Eric BoodmanJan. 20, 2026
General Assignment Reporter
Did my prostate cancer screening do more harm than good? Doctors still debate how to use the PSA test
https://www.statnews.com/2026/01/21/what-psa-screening-gets-wrong-prostate-cancer/
By Howard WolinskyJan. 21, 2026
Wolinsky is a Chicago-based medical journalist and publisher of The Active Surveillor, a Substack newsletter that covers lower-risk prostate cancer and active surveillance.
I’m getting the HPV vaccine at 24. That’s a problem Even before the childhood vaccine schedule’s update, doctors often overlooked the shot that can prevent cervical cancer
https://www.statnews.com/2026/01/21/hpv-vaccine-recommendation-age/
By Anamika ShrimaliJan. 21, 2026
Shrimali is a third-year medical student at Tufts University School of Medicine.
martes, 20 de enero de 2026
The Science Behind Sustainable Weight Loss and Weight Maintenance
https://www.news-medical.net/health/The-Science-Behind-Sustainable-Weight-Loss-and-Weight-Maintenance.aspx
Evidence shows that weight management outcomes are shaped not only by diet and exercise but also by timing, adherence, and clinical support. Initiating structured interventions early in the year aligns behavioral momentum with metabolic and medical strategies to improve long-term weight loss and disease risk reduction.
The Gut–Brain–Skin Axis: How Diet and Gut Health Influence Mood, Skin, and Aging
https://www.news-medical.net/health/The-Gute28093Braine28093Skin-Axis-How-Diet-and-Gut-Health-Influence-Mood-Skin-and-Aging.aspx
This article examines how diet-driven gut microbes influence interconnected pathways linking mood, inflammation, skin health, and aging through immune, metabolic, and neuroendocrine signaling. It synthesizes evidence on microbial metabolites, dietary patterns, and biomarkers to explain how the gut–skin–brain axis shapes systemic health.
Editorial e1 Management of diabetes during pregnancy The Lancet Obstetrics, Gynaecology, & Women's Health +...
Editorial
e1
Management of diabetes during pregnancy
The Lancet Obstetrics, Gynaecology, & Women's Health
https://www.thelancet.com/issue/S3050-5038(25)X0006-6
Corvus pill shows promise in early-stage eczema trial The company plans to advance its therapy in the competitive field
https://www.statnews.com/2026/01/20/corvus-pill-eczema-study-soquelitinib-dupixent/
By Adam FeuersteinJan. 20, 2026
Adam Feuerstein, a senior writer and biotech columnist, is the author of Adam’s Biotech Scorecard, a subscriber-only newsletter about the crossroads of drug development, business, Wall Street, and biotechnology.
How strong is the evidence for seaweed’s metabolic health benefits (Medscape AI)
https://www.medscape.com/ai-search?query=How%20strong%20is%20the%20evidence%20for%20seaweed%E2%80%99s%20metabolic%20health%20benefits&ecd=wnl_tp10_daily_260119_MSCPEDIT_etid8038049&uac=148436CN&impID=8038049
Seaweeds are nutritionally dense and contain a variety of bioactive compounds—including fibers, long-chain omega-3 fatty acids, polysaccharides, minerals (notably iodine), vitamins, and phytochemicals such as phlorotannins—that could favorably affect glucose and lipid metabolism. However, the current clinical research on their metabolic health effects remains limited in scope and quality.
Does open-angle glaucoma raise early-onset Alzheimer’s risk? (Medscape AI)
https://www.medscape.com/ai-search?query=Does%20open-angle%20glaucoma%20raise%20early-onset%20Alzheimer%E2%80%99s%20risk%3F&ecd=mkm_ret_260120_mscpmrk_ophth_latest-news_etid8035119&uac=148436CN&impID=8035119
Several observational analyses have examined the association between open-angle glaucoma (OAG) and the subsequent development of early-onset Alzheimer’s disease (AD).
We have the means to beat malaria, do we have the will? The Lancet Microbe ++... ++
We have the means to beat malaria, do we have the will?
The Lancet Microbe
https://www.thelancet.com/journals/lanmic/article/PIIS2666-5247(25)00264-2/fulltext?dgcid=raven_jbs_etoc_email
Jan 2026
Volume 7Number 1
https://www.thelancet.com/issue/S2666-5247(26)X0002-7
Attachment and replication of clade 2.3.4.4b influenza A (H5N1) viruses in human respiratory epithelium: an in-vitro study
Lisa Bauer, PhDa ∙ Lonneke Leijten, BSca ∙ Matteo Iervolino, MSca ∙ Varun Chopra, MScb ∙ Laura van Dijk, MSca ∙ Mark Power, MSca ∙ et al.
https://www.thelancet.com/journals/lanmic/article/PIIS2666-5247(25)00158-2/fulltext?dgcid=raven_jbs_etoc_feature_lanmic
Transmission of extended spectrum β-lactamase-producing Escherichia coli and antimicrobial resistance gene flow across One Health compartments in eastern Africa: a whole-genome sequence analysis from a prospective cohort study
Patrick Musicha, PhDa,b,c ∙ Mathew A Beale, PhDc ∙ Derek Cocker, PhDa,d ∙ Fiona A Oruru, MPHe ∙ Allan Zuza, MSca ∙ Chifundo Salifu, MSca ∙ et al.
https://www.thelancet.com/journals/lanmic/article/PIIS2666-5247(25)00152-1/fulltext?dgcid=raven_jbs_etoc_feature_lanmic
Editorial e173 Long may people-centred adaptation reign The Lancet Global Health ++... ++
Doing implementation otherwise: territory, trust, and the work of staying
Prof Ana María Arias-Uriona, PhD aarias.u@ucb.edu.bo ∙ Prof Marcela Losantos, PhD
https://www.thelancet.com/journals/langlo/article/PIIS2214-109X(25)00363-8/fulltext?dgcid=hubspot_update_feature_updatealerts_langlo&utm_campaign=update-langlo&utm_medium=email&_hsenc=p2ANqtz-9JAXhAIjXd7Q1nUs5YYCB8lL0tgKAj-dqgtyIyoxnDfggGHmfJ_Xip31cB5zwUM1Qp030e8iVYFtf1wxZ2srwJsjWdpA&_hsmi=399267773&utm_content=399256686&utm_source=hs_email
Editorial
e173
Long may people-centred adaptation reign
The Lancet Global Health
https://www.thelancet.com/journals/langlo/issue/vol14no2/PIIS2214-109X(25)X0014-0
Measuring co-design in global health research: methodological challenges and decolonial innovations
Prof Jenevieve Mannell, PhDa,b j.mannell@ucl.ac.uk ∙ Nwabisa Jama Shai, PhDc,d ∙ Natsayi Chimbindi, PhDa,e,f ∙ Andrew Gibbs, PhD
https://www.thelancet.com/journals/langlo/article/PIIS2214-109X(25)00438-3/fulltext?dgcid=hubspot_update_feature_updatealerts_langlo&utm_campaign=update-langlo&utm_medium=email&_hsenc=p2ANqtz-94e0U57iVvEiAmy6mv_3U9GCFDLtZrBsLUBce5HWrmf4i0-cZsVHrRNz1nGl-ikvPKk22b1I3M_IzoIT2hOvgoEB3__A&_hsmi=399267773&utm_content=399256686&utm_source=hs_email#
Safety and equity in scaling minimally invasive surgery worldwide in 109 countries using cholecystectomy as a tracer procedure: a prospective cohort study
NIHR Global Health Research Unit on Global Surgery and the GlobalSurg Collaborative
https://www.thelancet.com/journals/langlo/article/PIIS2214-109X(25)00476-0/fulltext?dgcid=hubspot_update_feature_updatealerts_langlo&utm_campaign=update-langlo&utm_medium=email&_hsenc=p2ANqtz-9GqnLbAiimK2dvAxoX0EDu1d2R9hjokeL7VcxmkkQ52j9wpbfbf8BVAX3t3QhHepkzw9soL_9dIC70AsoloJLVnpg0ag&_hsmi=399267773&utm_content=399256686&utm_source=hs_email
Future Approaches in Biliary Tract Cancer: Unmet Needs, Emerging Therapies, and Areas for Improvement. ++
https://pillsbtc.gruposaned.com/index.php/dr-angela-lamarca/?utm_source=saned&utm_medium=email&utm_campaign=saned_lamarca
Welcome back to the “Experience Pills: Practical Insights for the Early Diagnosis and Management of Biliary Tract Cancers (BTC)” program, a medical education initiative
designed to equip primary care and oncology specialists with the essential tools for early
detection and effective management of BTC, ultimately aiming to improve patient outcomes.
The program includes six video training pills, each accompanied by a detailed monograph,
that have been developed by a panel of international experts. The pills will be released progressively from October 2025 to January 2026.
You can now access the last training pill of this program.
lunes, 19 de enero de 2026
Does caffeine truly lower overall IBD risk, or does it hide subgroup harms (Medscape AI)
https://www.medscape.com/ai-search?query=Does%20caffeine%20truly%20lower%20overall%20IBD%20risk,%20or%20does%20it%20hide%20subgroup%20harms&ecd=wnl_tp10_daily_260118_MSCPEDIT_etid8034910&uac=148436CN&impID=8034910
Caffeine intake has been linked to a modest reduction in overall IBD susceptibility, but this association masks significant variation across patient subgroups.
Can routine vaccines lower dementia risk in older adults (Medscape AI)
https://www.medscape.com/ai-search?query=Can%20routine%20vaccines%20lower%20dementia%20risk%20in%20older%20adults&ecd=wnl_tp10_daily_260117_MSCPEDIT_etid8032703&uac=148436CN&impID=8032703
Routine adult immunizations confer protection against their target infections and have been linked in observational studies to lower risks of dementia among older adults.
Is a functional cure for HIV finally within reach? (Medscape AI)
Recent proof-of-concept trials suggest that long-acting immunotherapies may enable sustained virologic control off antiretroviral therapy (ART), raising the possibility of a functional HIV cure.
https://www.medscape.com/ai-search?query=Is%20a%20functional%20cure%20for%20HIV%20finally%20within%20reach%3f&ecd=mkm_ret_260119_mscpmrk_idhiv_HIVinfection_etid8035092&uac=148436CN&impID=8035092
Cancer might evade immune defences by stealing mitochondria Hijacking the energy-producing organelles from immune cells seems to help tumours in mice to infiltrate lymph nodes. By Laura Dattaro
https://www.nature.com/articles/d41586-026-00123-9?utm_source=Live+Audience&utm_campaign=fe625a50d4-nature-briefing-daily-20260115&utm_medium=email&utm_term=0_-33f35e09ea-50432164
Cancer cells use stolen goods to stay hidden
Cancer cells use mitochondria stolen from immune cells to escape detection and spread. Researchers found that when cancer cells take on these mitochondria in mice, it both weakens the immune cells and triggers a molecular pathway in the cancer cells that help them fly under the immune system’s radar and invade lymph nodes. This beneficial molecular pathway was activated even when researchers disrupted the mitochondria’s ability to produce the energy-carrying molecule ATP. The findings could explain how cancer cells survive in lymph nodes, which are packed with immune cells that should be able to kill them.
Ashwagandha aids recovery without blunting training stress in athletes
https://www.news-medical.net/news/20260118/Ashwagandha-aids-recovery-without-blunting-training-stress-in-athletes.aspx
A controlled trial in team-sport athletes suggests Ashwagandha may help maintain hormonal balance and support recovery and power adaptations during the physiological strain of pre-season training.
England’s North–South maternity mortality gap persists
https://www.news-medical.net/news/20260119/Englande28099s-Northe28093South-maternity-mortality-gap-persists.aspx
A decade-long analysis of England’s maternity services uncovers stark regional disparities in perinatal deaths. However, improvements are possible when struggling trusts learn from those that perform better.
Editorial Addressing the issue of ultra-processed foods The Lancet Healthy Longevity +++ +...
Oropharyngeal dysphagia: a narrative review towards an integrated neurogeriatric perspective
Bendix Labeit, MDa Bendix.Labeit@med.uni-duesseldorf.de ∙ Sriramya Lapa, PhDb ∙ Gero Lueg, MDc ∙ Rebecca Joebges, MDa ∙ Jule Hofacker, MSca ∙ Paul Muhle, MDd ∙ et al.
https://www.thelancet.com/journals/lanhl/article/PIIS2666-7568(25)00113-8/fulltext?dgcid=hubspot_update_feature_updatealerts_lanhl&utm_campaign=update-lanhl&utm_medium=email&_hsenc=p2ANqtz-9mn8NZDPZBlwxNgr2hHRd60IMrd7kcU4Si45_hw6D_QbqwEetPD91CEAiecFdvFDJzrn6_naF1Irg0EbIM-YHpl3g1CQ&_hsmi=399134278&utm_content=398256100&utm_source=hs_email
The association of pain with intrinsic capacity and the moderating role of inflammation in France: a cross-sectional analysis of the INSPIRE-T project
Federico Bellelli, MDa,b federicobellelli8@gmail.com ∙ Jeremy Raffin, PhDa,b ∙ Prof Matteo Cesari, MD PhDc ∙ Sophie Guyonnet, PhDa,b,d ∙ David Furman, PhDe ∙ Prof Yves Rolland, MD PhDf ∙ et al.
https://www.thelancet.com/journals/lanhl/article/PIIS2666-7568(25)00117-5/fulltext?dgcid=hubspot_update_feature_updatealerts_lanhl&utm_campaign=update-lanhl&utm_medium=email&_hsenc=p2ANqtz-8VCjqxjq67awYn_NVlBP52pwdS3gFF2n8pHSvTavqiJ1gJro4OHl0X8iOXTpR1JOSwZ14SJcJpEgX7pIcXcO2bmuMB6A&_hsmi=399134278&utm_content=398256100&utm_source=hs_email
Frailty and prognosis of biomarker-confirmed Alzheimer’s disease: a Swedish, register-based, retrospective cohort study
Xin Xia, PhDa xin.xia@ki.se ∙ Prof Maria Eriksdotter, MDb,c ∙ Prof Henrik Zetterberg, MDd,e,f,g,h,i,u,v ∙ Prof Silke Kern, MDj,k,l ∙ Tobias Skillbäck, PhDj,k ∙ Marco Toccaceli Blasi, MDm,n ∙ et al.
https://www.thelancet.com/journals/lanhl/article/PIIS2666-7568(25)00116-3/fulltext?dgcid=hubspot_update_feature_updatealerts_lanhl&utm_campaign=update-lanhl&utm_medium=email&_hsenc=p2ANqtz-_OOX9ihx4DF9eStmUxeQguB-Ia3FWeKoFkYenZldmWLCXvb258xeMaIlnMGY-9kXAhEPQRhoEfbOEbctgiGR1cZly22w&_hsmi=399134278&utm_content=398256100&utm_source=hs_email
Editorial
Addressing the issue of ultra-processed foods
The Lancet Healthy Longevity
https://www.thelancet.com/journals/lanhl/issue/vol6no12/PIIS2666-7568(25)X0013-1
RARE Revolution RARE Bite
https://editions.rarerevolutionmagazine.com/html5/reader/production/default.aspx?pubname=&edid=5fddfc62-9dc6-47bf-aa6a-922d41bce312&pnum=16
Following profound loss, Helene and Mikk Cederroth turned their grief into global action. Founding the Wilhelm Foundation, they have provided support and hope for undiagnosed families for over 25 years. With radical thinking they have fostered a community of global collaboration in the ongoing search for answers and recognition for those with undiagnosed diseases worldwide.
Aducanumab: advancing Alzheimer’s treatment through regulation of excessive β-amyloid accumulation Clotilde Nsimire Katana Kachungunu [1] , Subhash Namdeo Mashal [1] , Priyadarshi Soumyaranjan Sahu* [1]
https://www.academia.edu/academia-immunity-and-disease/1/2/10.20935/AcadImmunoDis8055
Abstract
Objective: Several drugs have been studied in past decades, with the main purpose of primarily being used for the symptomatic relief of Alzheimer’s Disease (AD). As of today, there are hundreds of ongoing studies to find a pharmacological treatment that will not only lessen the neurological symptoms of AD but will also slow down the progression or find a definite cure for the disease. We hypothesized that the emerging treatments for AD, such as Aducanumab, should primarily target the excessive brain accumulation of either β-amyloid peptides or tau proteins, thus delay the progression of illness when compared to the standard pharmacological treatment. The present systematic review explored and addressed Aducanumab therapy as an emerging treatment to cure, prevent, or slow down AD progression. Methods: A comprehensive literature search was conducted on PubMed using predefined search terms; the identified studies were then screened. Finally, 47 of the 210 articles were included for data extraction and analysis. Results: This study analyzed the validity and efficacy of Aducanumab. Aducanumab is a pharmacotherapy that targets excessive β-amyloid peptides in the brain; however, it does not have any role in reducing aggregated hyperphosphorylated tau proteins. Aducanumab has been analyzed and juxtaposed with the standard treatment, acetylcholinesterase inhibitors. Aducanumab is an effective pharmacotherapy that lowers β-amyloid peptides in the brain, and therefore, it helps treat AD. The side effects of Aducanumab are not deemed significant enough to justify FDA disapproval, and they can easily be monitored and prevented. Conclusions: Aducanumab has been proven to be a very effective and promising pharmacotherapy in treating AD. It is also the first disease-modifying pharmacotherapy for AD, and compared to the standard treatment, it is preferable in all aspects for slowing down or stopping the progression of AD.
MHC-II polymorphism in tuberculosis control: general lessons from focused studies in mice
Tatiana Kondratieva, Nadezhda Logunova, Alexander Apt
Volume 1, Issue 2
https://www.academia.edu/journals/academia-immunity-and-disease/articles?source=journal-top-nav
Reimagining enzyme function for synthetic biology and drug discovery
Reimagining enzyme function for synthetic biology and drug discovery
Enzymes once viewed as rigid specialists are now being repurposed as modular tools, revealing latent chemical capabilities and enabling new approaches to molecule construction.
https://www.drugdiscoverynews.com/reimagining-enzyme-function-for-synthetic-biology-and-drug-discovery-16926
A new approach could radically change erectile dysfunction treatment A new drug may restore sexual function for men for months after just three days of dosing, offering hope for those who don’t respond to existing therapies.
A new approach could radically change erectile dysfunction treatment
A new drug may restore sexual function for men for months after just three days of dosing, offering hope for those who don’t respond to existing therapies.
https://www.drugdiscoverynews.com/a-new-approach-could-radically-change-erectile-dysfunction-treatment-16910?utm_campaign=DDN_Newsletter_Science%20Spotlight&utm_medium=email&_hsenc=p2ANqtz-_cZJza5_FHK7JuSFKfMUDQlWD7YgecGZgOpbi_NIoPtNqCUObrj5uVBtrhPQyX57_U7o2t5fhQBxGliua0KyJJgd4KHw&_hsmi=398917420&utm_content=398917420&utm_source=hs_email
Conference Insights: Breaking Developments in ALK-Positive NSCLC and ES-SCLC Authors: Solange Peters, MD, PhD; Shirish M. Gadgeel, MD; Rafal Dziadziuszko, MD, PhD
https://www.medscape.org/viewarticle/conference-insights-breaking-developments-alk-positive-nsclc-2025a1000vwn?page=1%3Fsrc%3Dmkmcmr_reeng_recap_mscpedu_activity&uac=148436CN&sso=true
thank you for your recent participation in the activity:
Conference Insights: Breaking Developments in ALK-Positive NSCLC and ES-SCLC
Below are some key learning points to help reinforce the impact of this activity.
☑ Clinical Updates on ALK+ early-stage resectable non-small cell lung cancer (NSCLC):
• Alectinib has been approved as the first adjuvant ALK inhibitor for resectable early-stage ALK+ NSCLC based on ALINA, representing a major practice shift from chemotherapy-alone postoperative care.
• Updated ALINA results report a 4-year overall survival (OS) rate of 98.4% with alectinib, reinforcing its durable benefit in the adjuvant setting.
• Ensartinib has showed promising activity in the adjuvant setting, markedly improving 24-month disease-free survival (DFS) after complete resection 86.4% vs 53.5% with placebo, supporting its use as a postoperative therapy.
☑ Clinical Updates on extensive-stage small cell lung cancer (ES-SCLC):
• Lurbinectedin plus atezolizumab is a new approved option for first-line maintenance therapy for ES‑SCLC after completion of platinum‑etoposide with a PD‑L1 inhibitor.
• Based on IMforte, the combination improved median PFS (5.4 vs 2.1 months) and median OS (13.2 vs 10.6 months) vs atezolizumab alone, demonstrating a clinically meaningful benefit.
• Tarlatamab is moving from relapsed line monotherapy into earlier settings (with chemo-immunotherapy or as maintenance) to deepen and prolong responses.
• Tarlatamab in combination with a PD-L1 inhibitor as first-line maintenance after chemo-immunotherapy showed promising OS signals and high early survival, prompting the phase 3 DeLLphi 305 study.
domingo, 18 de enero de 2026
Researchers discover how Mycoplasma pneumoniae acquires cholesterol from human hosts
https://www.news-medical.net/news/20260116/Researchers-discover-how-Mycoplasma-pneumoniae-acquires-cholesterol-from-human-hosts.aspx
A multidisciplinary team has uncovered a key mechanism that allows the human bacterium Mycoplasma pneumoniae-responsible for atypical pneumonia and other respiratory infections-to obtain cholesterol and other essential lipids directly from the human body. The discovery, published in Nature Communications, was co-led by Dr. Noemí Rotllan, from the Sant Pau Research Institute (IR Sant Pau) and the Center for Biomedical Research in Diabetes and Associated Metabolic Disorders (CIBERDEM); Dr. Marina Marcos, from the Autonomous University of Barcelona (UAB); and Dr. David Vizarraga, from the Institute of Molecular Biology of Barcelona of the Spanish National Research Council (IBMB-CSIC) and the Center for Genomic Regulation (CRG). Overall coordination was led by Dr. Joan Carles Escolà-Gil, from IR Sant Pau and CIBERDEM; Dr. Jaume Piñol, from UAB; and Dr. Ignacio Fita, from IBMB-CSIC. The study also involved collaboration from the Institute of Biotechnology and Biomedicine of the UAB (IBB-UAB), the Center for Biomedical Research in Cardiovascular Diseases (CIBERCV), and other leading institutions.
Women and anxious people show distinct types of underconfidence
https://www.news-medical.net/news/20260116/Women-and-anxious-people-show-distinct-types-of-underconfidence.aspx
Women and people with anxiety are both prone to low confidence in their own abilities, but a new study by University College London (UCL) researchers has found that the two groups are prone to two distinct types of underconfidence.
New research compares different wellbeing-focused interventions delivered to adults
https://www.news-medical.net/news/20260116/New-research-compares-different-wellbeing-focused-interventions-delivered-to-adults.aspx
As another new year gets under way many of us will be looking for a way of boosting how we feel but is it better to hit the gym or mediate in nature? Now new research by Swansea experts has provided the largest ever comparison of wellbeing-focused interventions delivered to adults.
UK patients seeking surgery overseas are returning with complications the NHS must treat
A new review reveals how complications after overseas cosmetic and weight-loss surgery are landing back in UK hospitals, exposing serious risks for patients and unresolved pressures for the NHS.
https://www.news-medical.net/news/20260116/UK-patients-seeking-surgery-overseas-are-returning-with-complications-the-NHS-must-treat.aspx
Systems biology approaches for multi omics integration using artificial intelligence Shubham Yadav [1] , Jagannath Mondal [2] , Monochura Saha* [1,3]
https://www.academia.edu/2837-4010/4/1/10.20935/AcadBiol8077
Artificial Intelligence (AI) and machine learning (ML) are revolutionizing precision oncology by integrating and interpreting multi-omics data to uncover patient-specific biomarkers, predict therapeutic response, and guide personalized treatment strategies. AI-driven multi-omics integration faces challenges such as high dimensionality, data heterogeneity, and interpretability, which are critical for effective translation to precision oncology. This article provides a comprehensive overview of the current landscape and future trajectory of AI and ML in integrated multi-omics analysis for cancer research. The discussion explores the application of AI/ML across key omics modalities, including bulk RNA sequencing, single-cell RNA sequencing, spatial transcriptomics, and genomics, highlighting both individual and combined analytical approaches. The report elucidates advanced integration methodologies, including deconvolution, label transfer, and spatial mapping, alongside the inherent challenges of data heterogeneity, high dimensionality, and interpretability. Here, we further investigate real-world barriers to clinical translation, regulatory and ethical challenges, and demonstrate significant clinical impact through compelling case studies. This review explores current research gaps and outlines future directions, highlighting the contribution of AI-driven integrated omics in enhancing precision oncology.
Stressful conditions, photosynthesis and plantlets production: effects and management
Gustavo Alberto De la Riva, Verónica Gómez-Entzin, Ángel de Jesús Moles-Jiménez, Rolando Morán-Valdivia, Rolando García-González
Volume 4, Issue 1
https://www.academia.edu/journals/academia-biology/articles?source=journal-top-nav
When GLP-1s Fall Short: Some Patients Don’t Find Success Erica Lamberg January 06, 2026 +++
When GLP-1s Fall Short: Some Patients Don’t Find Success
Erica Lamberg
https://www.medscape.com/viewarticle/when-glp-1s-fall-short-some-patients-dont-find-success-2026a10000b9?ecd=mkm_ret_260118_mscpmrk_endo_perspectives_etid8034316&uac=148436CN&impID=8034316
January 06, 2026
Statins Show Benefit in T2D Even With Low Baseline CVD Risk
Miriam E. Tucker
https://www.medscape.com/viewarticle/statins-show-benefit-t2d-even-low-baseline-cvd-risk-2026a10000bl?ecd=mkm_ret_260118_mscpmrk_endo_perspectives_etid8034316&uac=148436CN&impID=8034316
January 06, 2026
New Dietary Guidelines: Eat More Meat and Whole-Fat Dairy
Alicia Ault
https://www.medscape.com/viewarticle/new-dietary-guidelines-eat-more-meat-and-whole-fat-dairy-2026a10000ln?ecd=mkm_ret_260118_mscpmrk_endo_perspectives_etid8034316&uac=148436CN&impID=8034316
January 08, 2026
The Removal of the Black Box on HT: Will Women’s Health Improve? JoAnn E. Manson, MD, DrPH January 05, 2026
The Removal of the Black Box on HT: Will Women’s Health Improve?
JoAnn E. Manson, MD, DrPH
https://www.medscape.com/viewarticle/removal-black-box-ht-will-womens-health-improve-2026a100003y?ecd=mkm_ret_260118_mscpmrk_endo_perspectives_etid8034316&uac=148436CN&impID=8034316
January 05, 2026
Homeless encampment at center of health alert over rat-borne disease By Melissa Rudy Fox News Published January 15, 2026 12:59pm EST
Homeless encampment at center of health alert over rat-borne disease
Berkeley health officials warn leptospirosis detected in rats and dogs poses serious risk to humans
Melissa Rudy By Melissa Rudy Fox News
Published January 15, 2026 12:59pm EST
https://www.foxnews.com/health/homeless-encampment-center-health-alert-over-rat-borne-disease
Oprah reveals struggle with 'shame' of weight-loss drugs and what happened when she quit By Angelica Stabile Fox News Published January 15, 2026 2:30pm EST
Oprah reveals struggle with 'shame' of weight-loss drugs and what happened when she quit
Famed talk show host says she's in the 'best shape of her life' at 71
Angelica Stabile By Angelica Stabile Fox News
Published January 15, 2026 2:30pm EST
https://www.foxnews.com/health/oprah-reveals-struggle-shame-weight-loss-drugs-what-happened-when-she-quit
Cancer survival rates reach record high, but deadliest types still put Americans at risk - American Cancer Society - By Angelica Stabile Fox News Published January 16, 2026 3:36pm EST
Cancer survival rates reach record high, but deadliest types still put Americans at risk
American Cancer Society announces cancer is 'becoming less of a death sentence'
Angelica Stabile By Angelica Stabile Fox News
Published January 16, 2026 3:36pm EST
https://www.foxnews.com/health/cancer-survival-rates-reach-record-high-deadliest-types-still-put-americans-risk
Doctor reveals health effects of 30 days without alcohol By Fox News Staff Fox News Published January 16, 2026 4:02pm EST | Updated January 16, 2026 4:09pm EST
Doctor reveals health effects of 30 days without alcohol
And more of this week's top health stories, right to your inbox
By Fox News Staff Fox News
Published January 16, 2026 4:02pm EST | Updated January 16, 2026 4:09pm EST
https://www.foxnews.com/health/whole-milk-headed-back-schools-more-weeks-biggest-health-stories
Doctors reveal what ‘reasonable’ drinking looks like — and who should avoid alcohol
Dr. Andrew Huberman and Dr. Ezekiel Emanuel discuss when social drinking becomes risky
Angelica Stabile By Angelica Stabile Fox News
Published January 16, 2026 7:00am EST
https://www.foxnews.com/health/doctors-reveal-what-reasonable-drinking-looks-like-who-should-avoid-alcohol
Heart study flags dangerous rhythm risk for endurance athletes over 50 By Peter Burke Fox News Published January 17, 2026 12:27pm EST
Heart study flags dangerous rhythm risk for endurance athletes over 50
Study suggests exercise may trigger abnormal rhythms in athletes with existing heart scarring
By Peter Burke Fox News
Published January 17, 2026 12:27pm EST
https://www.foxnews.com/health/heart-study-flags-dangerous-rhythm-risk-endurance-athletes-over-50
New research decodes the bacterial “zip code” of colorectal cancer for prediction and survival ++++
New research decodes the bacterial “zip code” of colorectal cancer for prediction and survival
https://www.news-medical.net/news/20260109/New-research-decodes-the-bacterial-e2809czip-codee2809d-of-colorectal-cancer-for-prediction-and-survival.aspx?utm_source=news_medical_newsletter&utm_medium=email&utm_campaign=bowel_cancer_newsletter_15_january_2026
Bacterial communities in colorectal cancer reveal patterns linked to tumor genetics and patient outcomes, paving the way for personalized treatment strategies.
A recent study shows that bacteria living inside colorectal tumors form distinct ecosystems that are closely linked to how the disease progression and patient outcomes. These “tissue-resident” microbes appear to play an integral role in shaping tumor biology, and can help predict patient survival more accurately than standard clinical factors alone.
Bowel preparation for colonoscopies may temporarily alter gut balance, preclinical study suggestsBowel preparation for colonoscopies may temporarily alter gut balance, preclinical study suggests
https://www.news-medical.net/news/20260108/Bowel-preparation-for-colonoscopies-may-temporarily-alter-gut-balance-preclinical-study-suggests.aspx?utm_source=news_medical_newsletter&utm_medium=email&utm_campaign=bowel_cancer_newsletter_15_january_2026
New preclinical research suggests that bowel preparation procedures for colonoscopies may temporarily alter gut balance, culminating in unappreciated effects in patients with compromised gastrointestinal health.
CNIO study identifies genes linked to pancreatic cancer risk and prognosisCNIO study identifies genes linked to pancreatic cancer risk and prognosis
https://www.news-medical.net/news/20260112/CNIO-study-identifies-genes-linked-to-pancreatic-cancer-risk-and-prognosis.aspx?utm_source=news_medical_newsletter&utm_medium=email&utm_campaign=bowel_cancer_newsletter_15_january_2026
A new study by the National Cancer Research Centre (CNIO) has identified several sets of genes related to the predisposition to develop pancreatic ductal adenocarcinoma (the most common type of pancreatic cancer), as well as the prognosis of the disease once it has appeared.
Novel liquid biopsy technology could advance cancer diagnostics and monitoringNovel liquid biopsy technology could advance cancer diagnostics and monitoring
https://www.news-medical.net/news/20260114/Novel-liquid-biopsy-technology-could-advance-cancer-diagnostics-and-monitoring.aspx?utm_source=news_medical_newsletter&utm_medium=email&utm_campaign=bowel_cancer_newsletter_15_january_2026
A novel liquid biopsy technology is set to advance cancer diagnostics and monitoring by overcoming the long-standing challenge of simultaneously achieving high sensitivity, broad coverage, and simple workflow.
Formulation and evaluation of chitosan-coated ketoconazole-loaded ethosomal gel by Box–Behnken design Anoop Kumar Chadoker [1] , Pooja Yadav [2] , Raj K. Keservani* [3] , Rohit Kumar Kesharwani [3]
https://www.academia.edu/academia-drug-development-and-pharmacotherapy/1/2/10.20935/AcadDrug7998
The research work aimed to evaluate the chitosan-coated ketoconazole-loaded ethosomal gel using a Box–Behnken design approach to increase bioavailability and reduce dose-related toxicity. In the design of experiment (DoE)-based formulation optimization, the independent variables were soy lecithin, Tween 80, and ethanol, while the dependent variables were particle size, polydispersity index (PDI), zeta potential (ZP), entrapment efficiency (EE), and cumulative percentage drug release (CDR). The design was a three-factor, three-level Box–Behnken design (BBD). The optimized ketoconazole (KCZ)-loaded ethosomes predicted by Design-Expert software (Version 13) consisted of 399.9 mg of soya lecithin, 4.73 ml of ethanol, and 300 µl of Tween 80, which were prepared by the cold method. According to characterization investigations, the mean particle size was 184.9 ± 6.21 nm, the zeta potential was −12.9 mV, the PDI was 0.230 ± 0.07, and the percentage of entrapment efficiency was 78.45 ± 3.5%. The observed CDR was 81.93 ± 5.6% at 24 h, exhibiting a sustained drug release profile. The optimized formulation was coated with chitosan to form a gel, with a pH of 5.5 and a viscosity of 9780 cps. In the in vitro antifungal study, the maximum zone of inhibition after 72 h, shown by chitosan-coated KCZ-loaded ethosomal, was 23.5 ± 5.3 mm. Edema was seen up to 72 h following the application of chitosan-coated KCZ-loaded ethosomes, but there was no indication of erythema in the in vivo skin irritation assay. The results showed that this formulation showed good potential for antifungal activity against Candida albicans.
Nanomedicines in the treatment of methicillin-resistant Staphylococcus aureus
Anurag Yadav, Kusum Yadav
Volume 2, Issue 1
https://www.academia.edu/journals/academia-drug-development-and-pharmacotherapy/articles?source=journal-top-nav
Microplastics and Your Health: What to Know Emily Berry January 16, 2026 +++
Microplastics and Your Health: What to Know
Emily Berry
https://www.medscape.com/s/viewarticle/microplastics-and-your-health-what-know-2026a10001h2?ecd=wnl_edit_tpal_etid8035928&uac=148436CN&impID=8035928
January 16, 2026
When Can Immunotherapy Stop in Melanoma? Meta-analysis Offers Guidance
Maurie Markman, MD
https://www.medscape.com/viewarticle/when-can-immunotherapy-stop-melanoma-meta-analysis-offers-2025a100101x?ecd=wnl_edit_tpal_etid8035928&uac=148436CN&impID=8035928
January 16, 2026
Fast Five Quiz: Adjuvant Therapy for Non-Small Cell Lung Cancer
Reviewed by Maurie Markman, MD
https://reference.medscape.com/viewarticle/adjuvant-therapy-nsclc-2025a1000y5y?ecd=wnl_edit_tpal_etid8035928&uac=148436CN&impID=8035928
January 16, 2026
Suscribirse a:
Comentarios (Atom)
